All stock lists
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
3.59-0.29 (-7.47%)
Market cap
$217M
Insider Score
Health Score
Analyst consensus
Listed since
Apr 12, 2006
Website
Insider Score
92/ 100
VNDA Insider Score
Bullish3 qualifying trades · 1 insider · $38.09K bought in the last 90 days
VNDA analyst forecast
VNDA analyst consensus
Moderate Buy2 ratings
Buy 2 Hold 0 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
VNDA 12-month price target
$10.00+178.6% upsideaverage of 1 firm
$10.00High
$10.00Low
VNDA ratings mix, last 12 months
Buy Hold Sell
Best analysts covering VNDA
- HC Wainwright & Co.100%success rate · +52.5% avg return · 8 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
VNDA analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-10-05 |
| Oppenheimer | — | $10.00 | +91.9% | — | 2026-09-23 | |
| — | B. Riley Securities | Buy | — | — | Reiterated | 2026-08-10 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-08-10 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-05-11 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-02-23 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-01-05 |
| — | B. Riley Securities | Buy | — | — | Reiterated | 2025-12-31 |
| — | Jefferies | Hold | — | — | Reiterated | 2025-12-31 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-11-19 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2025-10-30 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-08-21 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-05-07 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-04-01 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-02-18 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-02-04 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-01-28 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-01-21 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-12-23 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-08-01 |
| — | Jefferies | Hold | — | — | Downgraded | 2022-02-25 |
| — | B of A Securities | Buy | — | — | Reiterated | 2021-05-12 |
| — | Citigroup | Neutral | — | — | Downgraded | 2021-01-14 |
| — | Citigroup | Buy | — | — | Upgraded | 2020-10-29 |
| — | Citigroup | Neutral | — | — | Downgraded | 2020-06-09 |
| — | Citigroup | Buy | — | — | Upgraded | 2020-03-12 |
| — | JMP Securities | Market Outperform | — | — | Reiterated | 2020-02-26 |
| — | Stifel | Hold | — | — | Reiterated | 2020-02-26 |
| — | Citigroup | Buy | — | — | Upgraded | 2019-08-01 |
| — | Citi | Buy | — | — | Upgraded | 2019-08-01 |
| — | Stifel | Hold | — | — | Downgraded | 2019-07-25 |
| — | Stifel Nicolaus | Hold | — | — | Downgraded | 2019-07-25 |
| — | Cantor Fitzgerald | Neutral | — | — | Downgraded | 2019-02-06 |
| — | Stifel Nicolaus | Buy | — | — | Reiterated | 2018-12-11 |
| — | Oppenheimer | Perform | — | — | Downgraded | 2018-12-11 |
| — | Stifel | Buy | — | — | Reiterated | 2018-12-11 |
| — | Citigroup | Buy | — | — | Reiterated | 2018-12-07 |
| — | JMP Securities | Market Outperform | — | — | Reiterated | 2018-12-06 |
| — | Cantor Fitzgerald | Overweight | — | — | Upgraded | 2018-12-04 |
| — | Jefferies | Buy | — | — | Reiterated | 2018-11-08 |
| — | Citigroup | Buy | — | — | Reiterated | 2018-10-16 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2018-09-21 |
| — | Stifel Nicolaus | Buy | — | — | Reiterated | 2018-09-14 |
| — | Cantor Fitzgerald | Neutral | — | — | Reiterated | 2018-08-23 |
| — | Citigroup | Buy | — | — | Reiterated | 2018-05-23 |
| — | Seaport Global | Buy | — | — | Reiterated | 2018-01-19 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2017-10-30 |
| — | H.C. Wainwright | Buy | — | — | Reiterated | 2017-05-26 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2017-04-12 |
| — | Aegis Capital | Buy | — | — | Reiterated | 2016-11-09 |
| — | JMP Securities | Market Outperform | — | — | Reiterated | 2016-08-26 |
| — | PiperJaffray | Overweight | — | — | Reiterated | 2016-08-24 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2016-08-24 |
| — | JMP Securities | Market Outperform | — | — | Reiterated | 2016-03-09 |
| — | Brean Capital | Buy | — | — | Reiterated | 2015-10-21 |
| — | Jefferies | Buy | — | — | Reiterated | 2015-03-09 |
| — | Jefferies | Market Outperform | — | — | Reiterated | 2015-02-20 |
| — | Empire Asset Management | Sell | — | — | Reiterated | 2014-06-10 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2014-02-13 |
| — | PiperJaffray | Overweight | — | — | Reiterated | 2014-02-13 |
VNDA earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-02-11 | -2.18 | -2.39 | $59.3M | $57.2M |
| 2026-05-06 | -0.53 | -0.82 | $55.0M | $51.7M |
| 2026-08-05 | -0.58 | -1.04 | $61.9M | $50.5M |
| 2026-10-28 | -0.68 | -0.37 | $69.2M | $69.8M |
| 2027-02-10Upcoming | -0.32 | — | $70.1M | — |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.